Printer-friendly versionSend by emailPDF version

IMI Consortia Members

 

CDISC IMI relationship:

 

The Innovative Medicines Initiative (IMI) is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The IMI is the world’s largest public-private partnership initiative aiming to speed up the development of better and safer medicines.

With a €2 billion research fund, IMI supports collaborative projects through consortia comprising academic experts, small and medium-sized enterprises, patients’ organisations, pharmaceutical companies, and regulators to support innovation in research and development in Europe. IMI projects range from finding new biomarkers for the development of safer and more effective treatments for patients, to educating researchers and using electronic health records for various research purposes.

 

The IMI and CDISC are working together to enhance the use of information gathered for the purpose of developing safer, more effective innovative medicines for patients.

 

All consortia members receive the benefits of CDISC Platinum Membership.